Unknown

Dataset Information

0

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.

ABSTRACT: Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n?=?151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low-risk, 45 (39%) intermediate-1 risk, 42 (36%) intermediate-2, and 12 (10%) high-risk. 35 (23%) patients received single agent azacitidine, 73 (48%) single agent decitabine, and 43 (29%) combinations. With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR). Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17). By multivariate analysis, age?

SUBMITTER: Alfonso A 

PROVIDER: S-EPMC5553721 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low-risk, 45 (39%) intermediate-1  ...[more]

Similar Datasets

Unknown Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
| S-EPMC6013781 | biostudies-literature
Unknown Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
| S-EPMC7789782 | biostudies-literature
Unknown Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
| S-EPMC4770084 | biostudies-literature
Unknown A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
| S-EPMC6570401 | biostudies-literature
Unknown Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
| S-EPMC8095152 | biostudies-literature
Unknown Genomic determinants of chronic myelomonocytic leukemia.
| S-EPMC8370480 | biostudies-literature
Unknown The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
| S-EPMC6457217 | biostudies-literature
Unknown Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
| S-EPMC6540984 | biostudies-literature
Unknown Age-related mutations and chronic myelomonocytic leukemia.
| S-EPMC5096889 | biostudies-literature
Unknown Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.
| S-EPMC6939510 | biostudies-literature